Özet:
Aim: Diabetic neuropathy is one of the chronic complications of diabetes. Our aim in this study is to examine the effects of spinorphine on painful diabetic neuropathy in vivo.
Material and Methods: Seventy-five three-week rats were used. The first group was determined as a healthy control group (n = 15). Then, diabetic animals were grouped into subassemblies following induction in rats induced streptozotocin and diabetes. Groups were created using rat as follows: First group: Healthy control group, Second group: Diabetic control group (group to be given spinorphine solvent) (n = 15), Third group: DM + SP0.1 group (group to be applied 0.1 mg / kg spinorphine) (n = 15), Fourth Group: DM + SP1 group (group to be applied 1 mg / kg spinorphine) (n = 15) and Fifth group: DM + SP5 group (group to be applied 5 mg / kg spinorphine) (n = 15).
Results: When the diabetic control group and the healthy control group were compared in terms of the pain threshold values, a statistically significant difference was found (P<0.05). This result was considered significant in regards to the development of neuropathy (P<0.05). The pain threshold values in DM + SP0.1 and DM + SP1 groups had no statistically significant differences compared with the diabetic control group (P>0.05).
Discussion: This study, found spinorphine to be effective at doses of 5mg/kg or higher and when administrated intraperitoneally in the acute antinociceptive treatment of painful neuropathy in diabetic rats.
